Developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible.

In November 2022, ARS Pharmaceuticals and Silverback Therapeutics completed their merger, officially combining into a single publicly traded company under the name ARS Pharmaceuticals.